189 related articles for article (PubMed ID: 34158057)
1. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
Schwartz GG; Nicholls SJ; Toth PP; Sweeney M; Halliday C; Johansson JO; Wong NCW; Kulikowski E; Kalantar-Zadeh K; Ginsberg HN; Ray KK
Cardiovasc Diabetol; 2021 Jun; 20(1):125. PubMed ID: 34158057
[TBL] [Abstract][Full Text] [Related]
2. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
Nicholls SJ; Schwartz GG; Buhr KA; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Sweeney M; Ray KK;
Cardiovasc Diabetol; 2021 Jan; 20(1):13. PubMed ID: 33413345
[TBL] [Abstract][Full Text] [Related]
3. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Ray KK; Nicholls SJ; Ginsberg HD; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Cummings JL; Sweeney M; Schwartz GG
Am Heart J; 2019 Nov; 217():72-83. PubMed ID: 31520897
[TBL] [Abstract][Full Text] [Related]
4. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
Ray KK; Nicholls SJ; Buhr KA; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Sweeney M; Schwartz GG;
JAMA; 2020 Apr; 323(16):1565-1573. PubMed ID: 32219359
[TBL] [Abstract][Full Text] [Related]
5. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
[TBL] [Abstract][Full Text] [Related]
6. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.
Kalantar-Zadeh K; Schwartz GG; Nicholls SJ; Buhr KA; Ginsberg HN; Johansson JO; Kulikowski E; Lebioda K; Toth PP; Wong N; Sweeney M; Ray KK;
Clin J Am Soc Nephrol; 2021 May; 16(5):705-716. PubMed ID: 33906908
[TBL] [Abstract][Full Text] [Related]
7. Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
Stähli BE; Nozza A; Schrieks IC; Buse JB; Malmberg K; Mellbin L; Neal B; Nicholls SJ; Rydén L; Svensson A; Wedel H; Weichert A; Lincoff AM; Grobbee DE; Tardif JC; Schwartz GG
J Clin Endocrinol Metab; 2018 Jul; 103(7):2522-2533. PubMed ID: 29659887
[TBL] [Abstract][Full Text] [Related]
8. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
9. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.
Haarhaus M; Ray KK; Nicholls SJ; Schwartz GG; Kulikowski E; Johansson JO; Sweeney M; Halliday C; Lebioda K; Wong N; Brandenburg V; Beddhu S; Tonelli M; Zoccali C; Kalantar-Zadeh K
Atherosclerosis; 2019 Nov; 290():59-65. PubMed ID: 31568963
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.
Wijkman MO; Claggett B; Diaz R; Gerstein HC; Køber L; Lewis E; Maggioni AP; Wolsk E; Aguilar D; Bentley-Lewis R; McMurray JJ; Probstfield J; Riddle M; Tardif JC; Solomon SD; Pfeffer MA
Cardiovasc Diabetol; 2020 Oct; 19(1):175. PubMed ID: 33046070
[TBL] [Abstract][Full Text] [Related]
11. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
Verma S; Bain SC; Buse JB; Idorn T; Rasmussen S; Ørsted DD; Nauck MA
JAMA Cardiol; 2019 Dec; 4(12):1214-1220. PubMed ID: 31721979
[TBL] [Abstract][Full Text] [Related]
12. Apabetalone - BET protein inhibition in cardiovascular disease and Type 2 diabetes.
Brandts J; Ray KK
Future Cardiol; 2020 Sep; 16(5):385-395. PubMed ID: 32378426
[TBL] [Abstract][Full Text] [Related]
13. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
[TBL] [Abstract][Full Text] [Related]
14. Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.
Hoogwerf BJ; Lincoff AM; Rodriguez A; Chen L; Qu Y
Cardiovasc Diabetol; 2016 May; 15():78. PubMed ID: 27188479
[TBL] [Abstract][Full Text] [Related]
15. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ostadal P; Steg PG; Poulouin Y; Bhatt DL; Bittner VA; Chua T; Diaz R; Goodman SG; Huo Y; Jukema JW; Karpov Y; Pordy R; Scemama M; Szarek M; White HD; Schwartz GG;
Lancet Diabetes Endocrinol; 2022 May; 10(5):330-340. PubMed ID: 35378068
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
17. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
[TBL] [Abstract][Full Text] [Related]
18. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
[TBL] [Abstract][Full Text] [Related]
19. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Bittner VA; Szarek M; Aylward PE; Bhatt DL; Diaz R; Edelberg JM; Fras Z; Goodman SG; Halvorsen S; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Moriarty PM; Moryusef A; Pordy R; Roe MT; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
J Am Coll Cardiol; 2020 Jan; 75(2):133-144. PubMed ID: 31948641
[TBL] [Abstract][Full Text] [Related]
20. Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI.
Chandrasekhar J; Dangas G; Baber U; Sartori S; Qadeer A; Aquino M; Vogel B; Faggioni M; Vijay P; Claessen BE; Goel R; Moreno P; Krishnan P; Kovacic JC; Kini A; Mehran R; Sharma S
Catheter Cardiovasc Interv; 2020 Aug; 96(2):298-308. PubMed ID: 32162781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
